Applied DNA Sciences Shares Triples After Monkeypox Diagnostic Test Update - Applied DNA Sciences (NASDAQ:APDN)

Applied DNA Sciences Inc APDN has initiated analytical validation of a company-developed, PCR-based monkeypox virus test specific to the genetic signature of the monkeypox virus.
The test has been developed as an NYSDOH Laboratory Developed Test (LDT) type.
If Applied DNA validates the test, a validation package will be submitted to the New York State Department of Health (NYSDOH) for approval.
If approved, the test will be used to power ADCL's monkeypox testing services.
Applied DNA's monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of the monkeypox virus from other non-variola orthopoxviruses using real-time PCR.
California Governor Gavin Newsom declared a state of emergency over the monkeypox.
California confirmed 827 monkeypox cases, the second-largest state tally after the 1,390 infections documented in New York, according to the U.S. Centers for Disease Control and Prevention.
Price Action: APDN shares are up 236.3% at $2.29 during the market session on the last check Tuesday.